Dipeptide compound or pharmaceutically acceptable salt thereof a

Details Dipeptide compound or pharmaceutically acceptable salt thereof a Dipeptide compound or pharmaceutically acceptable salt thereof a

1996-06-26

1999-08-03

Budens, Robert D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

4241851, 530333, 530336, 530337, 2609982, A61K 3805, C07K 506, C07K 106

Patent

active

059325500

ABSTRACT:
The present invention provides a novel dipeptide compound or pharmaceutically acceptable salt thereof which exhibits an excellent HIV protease inhibitory activity and an excellent bioavailability from digestive tracts, and an anti-AIDS agent comprising said dipeptide compound as an effective ingredient.
General formula (I): ##STR1## (wherein R.sub.1 represents 5-membered or 6-membered monocyclic hydrocarbon group or heterocyclic group wherein more than one carbon atom of said monocyclic hydrocarbon group is substituted with hetero atom. X represents methylene group (--CH.sub.2 --), chloromethylene group(--CH(Cl)--), oxygen atom sulfur atom or sulfonyl group (--SO.sub.2 --). R.sub.21 and R.sub.22 each represents hydrogen atom or aliphatic hydrocarbon group having 1-6 carbons. R.sub.3 represents aliphatic hydrocarbon group or monovalent group derived from aromatic monocyclic hydrocarbon having 1-6 carbons.)

REFERENCES:
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5086165 (1992-02-01), Marshall et al.
patent: 5126326 (1992-06-01), Anderson et al.
patent: 5132400 (1992-07-01), Gammill et al.
patent: 5145951 (1992-09-01), Voges et al.
patent: 5187074 (1993-02-01), Treiber et al.
patent: 5188950 (1993-02-01), Balani et al.
patent: 5192668 (1993-03-01), Treiber et al.
patent: 5212157 (1993-05-01), Anderson et al.
patent: 5342922 (1994-08-01), Marshall et al.
patent: 5434265 (1995-07-01), Fritz et al.
patent: 5438118 (1995-08-01), Callahan et al.
patent: 5475013 (1995-12-01), Talley et al.
patent: 5476874 (1995-12-01), Hungate et al.
patent: 5491166 (1996-02-01), Kaldor et al.
patent: 5492910 (1996-02-01), Barrish et al.
patent: 5502060 (1996-03-01), Thompson et al.
patent: 5502061 (1996-03-01), Hui et al.
patent: 5514802 (1996-05-01), Fritz et al.
patent: 5644028 (1997-07-01), Mimoto et al.
Baldwin et al. (1995), "Structure of HIV-1 Protease With KNI-272, A Tight-Binding Transition-State Analog Containing Allophenylnorstatine," Structure 581-590.
Kiso (1995), "Design and Synthesis of HIV Protease Inhibitors Containing Allophenylnorstatine As A Transition-State Mimic," Aspartic Proteinases Structure, Function, Biology and Biomedical Implications, Ed. Kenji Takahashi, Plenum Press, NY, pp. 414-423.
Gulnik et. al. (1995), "Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutant Selected under Drug Pressure," Biochemistry, vol. 34, No. 29, 9282-9287.
Kageyama et al. (1993), "In Vitro Anti-Human Immunodeficiency Virus (HIV) Activities of Transition State Mimetic HIV Protease Inhibitors Containing Allophenylnorstatine," 37 Antimicrob. Agents & Chemo. 4:810-817.
Humphrey et al. (1997), "Removal of Human Immunodeficiency Virus Type I (HIV-1) Protease Inhibitors From Preparations of Immature HIV-1 Virions Does Not Result in an Increase in Infectivity or the Appearance of Mature Morphology," 41 Antimicrob. Agents & Chemo. 5:1017-1023.
Uchida et al. (1997), "HIV-1 Protease Does Not Play A Critical Role In The Early Stages of HIV-1 Infection," Antiviral Research 107-113.
Fahoy et al, Clin. Exp. Immunol. 88:1-5, 1992.
Fox, J.L., Bio/Technology 12:128, Feb. 1994.
Haynes et al., Ann. Med. 28:39-41, 1996.
Gulnik et. al. (1995), "Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutant Selected under Drug Pressure," Biochemistry, vol. 34, No. 29, 9282-9287.
Kageyama et al. (1993), "In Vitro Anti-Human Immunodeficiency Virus (HIV) Activities of Transition State Mimetic HIV Protease Inhibitors Containing Allophenylnorstatine," 37 Antimicrob. Agents & Chemo. 4:810-817.
Humphrey et al. (1997), "Removal of Human Immunodeficiency Virus Type I (HIV-1) Protease Inhibitors From Preparations of Immature HIV-1 Virions Does Not Result in an Increase in Infectivity or the Appearance of Mature Morphology," 41 Antimicrob. Agents & Chemo. 5:1017-1023.
Uchida et al. (1997), "HIV-1 Protease Does Not Play A Critical Role In The Early Stages of HIV-1 Infection," 36 Antiviral Research 107-113.
N.A. Roberts et al., "Rational Design of Peptide-Based HIV Proteinase Inhibitors" Science 248:358-362 (1990).
T. Robins et al., "HIV Protease Inhibitors: Their Anti-HIV Activity and Potential Role in Treatment" J. Acquired Immune Deficiency Syndromes 6(2):162-170 (1993).
Communications to the Editor, "Intriguing Structure--Activity Relations Underlie the Potent Inhibition of HIV Protease by Norstatine-Based Peptides" J. Med. Chem. 35:1318-1320 (1992).

Affiliated with

Also associated with

Rating

Dipeptide compound or pharmaceutically acceptable salt thereof a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dipeptide compound or pharmaceutically acceptable salt thereof a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptide compound or pharmaceutically acceptable salt thereof a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-849492